Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias

NCT01445080 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01445080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01445080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
May 30, 2006
Completion date
December 10, 2012
Enrollment
70 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

blastic phase, childhood acute promyelocytic leukemia with pml-rara, childhood chronic myelogenous leukemia, bcr-abl1 positive, childhood solid neoplasm, chronic myelogenous leukemia, bcr-abl1 positive, juvenile myelomonocytic leukemia, philadelphia chromosome negative, bcr-abl1 positive chronic myelogenous leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent disease